Skip to main content
Premium Trial:

Request an Annual Quote

The Genetic Testing Fray Keeps Growing

Hsien-Hsien Lei reports that three companies, Neuromark, Psynomics, and SureGene, are now offering genetic tests for mental illness variants. Neuromark’s Mark-C test will test for markers GRIK2 and GRIA3, which are believed to increase the risk of suicidal thoughts in people on Celexa. Psynome tests for two mutations in the GRK3 gene associated with bipolar disorder. SureGene's AssureGene test will look at genes associated with patients at risk of developing psychosis. Having one or two susceptibility markers doesn't mean someone will develop a disease, so, obviously, says Lei, the risk of misinformation is there. "I can’t say for sure that these companies are not providing proper customer service and information," she writes at Eye on DNA.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.